Cargando…

Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer

A case of a woman in her 60s with breast cancer, whose leptomeningeal metastasis (LM) of breast cancer improved remarkably with letrozole monotherapy, is reported. The patient complained of numbness of her left hand and hoarseness, followed by progressive asymmetric extremity weakness and a bladder...

Descripción completa

Detalles Bibliográficos
Autores principales: Takanashi, Toshihiro, Hikino, Hajime, Makino, Yoshinari, Murata, Yoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744529/
https://www.ncbi.nlm.nih.gov/pubmed/31559112
http://dx.doi.org/10.1007/s13691-019-00372-8
_version_ 1783451391062179840
author Takanashi, Toshihiro
Hikino, Hajime
Makino, Yoshinari
Murata, Yoko
author_facet Takanashi, Toshihiro
Hikino, Hajime
Makino, Yoshinari
Murata, Yoko
author_sort Takanashi, Toshihiro
collection PubMed
description A case of a woman in her 60s with breast cancer, whose leptomeningeal metastasis (LM) of breast cancer improved remarkably with letrozole monotherapy, is reported. The patient complained of numbness of her left hand and hoarseness, followed by progressive asymmetric extremity weakness and a bladder and rectal disturbance. The patient had undergone surgery for left breast cancer 18 years earlier and was concerned about recurrence of breast cancer, but there were no typical findings with some imaging modalities. The third lumbar puncture showed the malignant cytology of breast cancer, and the patient was diagnosed with recurrent breast cancer. Her performance status was very poor, and it was difficult to administer systemic chemotherapy. Letrozole was started because immunohistochemistry was positive for estrogen and progesterone receptors. After 4 months of letrozole therapy, the symptoms improved gradually. LM has a poor prognosis, and there is little evidence on which to base treatment, but hormone therapy may be an option for LM when the tumor is hormone receptor-positive, slow growing, and has a small volume.
format Online
Article
Text
id pubmed-6744529
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-67445292019-09-26 Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer Takanashi, Toshihiro Hikino, Hajime Makino, Yoshinari Murata, Yoko Int Cancer Conf J Case Report A case of a woman in her 60s with breast cancer, whose leptomeningeal metastasis (LM) of breast cancer improved remarkably with letrozole monotherapy, is reported. The patient complained of numbness of her left hand and hoarseness, followed by progressive asymmetric extremity weakness and a bladder and rectal disturbance. The patient had undergone surgery for left breast cancer 18 years earlier and was concerned about recurrence of breast cancer, but there were no typical findings with some imaging modalities. The third lumbar puncture showed the malignant cytology of breast cancer, and the patient was diagnosed with recurrent breast cancer. Her performance status was very poor, and it was difficult to administer systemic chemotherapy. Letrozole was started because immunohistochemistry was positive for estrogen and progesterone receptors. After 4 months of letrozole therapy, the symptoms improved gradually. LM has a poor prognosis, and there is little evidence on which to base treatment, but hormone therapy may be an option for LM when the tumor is hormone receptor-positive, slow growing, and has a small volume. Springer Singapore 2019-04-19 /pmc/articles/PMC6744529/ /pubmed/31559112 http://dx.doi.org/10.1007/s13691-019-00372-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Case Report
Takanashi, Toshihiro
Hikino, Hajime
Makino, Yoshinari
Murata, Yoko
Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title_full Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title_fullStr Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title_full_unstemmed Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title_short Durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
title_sort durable clinical benefit of letrozole in leptomeningeal metastasis of breast cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6744529/
https://www.ncbi.nlm.nih.gov/pubmed/31559112
http://dx.doi.org/10.1007/s13691-019-00372-8
work_keys_str_mv AT takanashitoshihiro durableclinicalbenefitofletrozoleinleptomeningealmetastasisofbreastcancer
AT hikinohajime durableclinicalbenefitofletrozoleinleptomeningealmetastasisofbreastcancer
AT makinoyoshinari durableclinicalbenefitofletrozoleinleptomeningealmetastasisofbreastcancer
AT muratayoko durableclinicalbenefitofletrozoleinleptomeningealmetastasisofbreastcancer